[go: up one dir, main page]

MX2016014997A - Compuestos piridinicos de pladienolida y metodos de uso. - Google Patents

Compuestos piridinicos de pladienolida y metodos de uso.

Info

Publication number
MX2016014997A
MX2016014997A MX2016014997A MX2016014997A MX2016014997A MX 2016014997 A MX2016014997 A MX 2016014997A MX 2016014997 A MX2016014997 A MX 2016014997A MX 2016014997 A MX2016014997 A MX 2016014997A MX 2016014997 A MX2016014997 A MX 2016014997A
Authority
MX
Mexico
Prior art keywords
methods
compounds
pyridine compounds
pladienolide pyridine
pladienolide
Prior art date
Application number
MX2016014997A
Other languages
English (en)
Other versions
MX373324B (es
Inventor
Tivitmahaisoon Parcharee
Nagao Satoshi
Wang John
Prajapati Sudeep
Liu Xiang
F Keaney Gregg
Gerard Baudouin
Arai Kenzo
Kira Kazunobu
Kotake Yoshihiko
Kanada SONOBE Regina
Miyano Masayuki
Murai Norio
Zhu Zheng Guo
C Gearhart Nicholas
Buonamici Silvia
Lihua Yu
Sun PARK Eunice
Chan Betty
G Smith Peter
p thomas Michael
Pazolli Ermira
Huat LIM Kian
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53284528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016014997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2016014997A publication Critical patent/MX2016014997A/es
Publication of MX373324B publication Critical patent/MX373324B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención provee compuestos piridínicos de pladienolida novedosos, composiciones farmacéuticas que los contienen, y métodos para usar los compuestos como agentes terapéuticos. Estos compuestos pueden ser útiles en el tratamiento del cáncer, particularmente cánceres en los cuales se conoce que son útiles los agentes que están dirigidos al spliceosoma y mutaciones en el mismo.
MX2016014997A 2014-05-15 2015-05-13 Compuestos piridínicos de pladienolida y métodos de uso. MX373324B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993423P 2014-05-15 2014-05-15
PCT/US2015/030464 WO2015175594A1 (en) 2014-05-15 2015-05-13 Pladienolide pyridine compounds and methods of use

Publications (2)

Publication Number Publication Date
MX2016014997A true MX2016014997A (es) 2017-06-29
MX373324B MX373324B (es) 2020-05-04

Family

ID=53284528

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016014997A MX373324B (es) 2014-05-15 2015-05-13 Compuestos piridínicos de pladienolida y métodos de uso.
MX2020004476A MX388580B (es) 2014-05-15 2015-05-13 Compuestos piridinicos de pladienolida y metodos de uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020004476A MX388580B (es) 2014-05-15 2015-05-13 Compuestos piridinicos de pladienolida y metodos de uso

Country Status (36)

Country Link
US (1) US9481669B2 (es)
EP (2) EP3143016B1 (es)
JP (1) JP6067943B1 (es)
KR (2) KR101710318B1 (es)
CN (1) CN107074827B (es)
AR (1) AR100431A1 (es)
AU (1) AU2015259237B2 (es)
BR (1) BR112016026638B1 (es)
CA (1) CA2947754C (es)
CL (1) CL2016002835A1 (es)
CY (1) CY1121550T1 (es)
DK (1) DK3143016T3 (es)
ES (1) ES2712401T3 (es)
HR (1) HRP20190432T1 (es)
HU (1) HUE041838T2 (es)
IL (1) IL248529B (es)
JO (1) JO3668B1 (es)
LT (1) LT3143016T (es)
MA (1) MA39915B1 (es)
ME (1) ME03417B (es)
MX (2) MX373324B (es)
MY (1) MY195081A (es)
PE (1) PE20170384A1 (es)
PH (1) PH12016502249B1 (es)
PL (1) PL3143016T3 (es)
PT (1) PT3143016T (es)
RS (1) RS58400B1 (es)
RU (1) RU2707730C2 (es)
SG (1) SG11201609693XA (es)
SI (1) SI3143016T1 (es)
SM (1) SMT201900158T1 (es)
TR (1) TR201902328T4 (es)
TW (1) TWI634115B (es)
UA (1) UA119458C2 (es)
WO (1) WO2015175594A1 (es)
ZA (1) ZA201607354B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10889866B2 (en) 2015-09-01 2021-01-12 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic SF3B1 mutants
JP6312282B2 (ja) 2015-11-18 2018-04-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 固体形態のプラジエノライドピリジン化合物及び使用の方法
CN110914457A (zh) 2017-03-15 2020-03-24 卫材研究发展管理有限公司 剪接体突变及其用途
CA3079089A1 (en) * 2017-10-31 2019-05-09 Eisai R&D Management Co., Ltd. Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors and methods of use
JOP20200242A1 (ar) * 2018-04-09 2020-09-29 Eisai R&D Man Co Ltd مركبات البلاديينوليد واستخداماتها
KR20250114141A (ko) * 2018-04-12 2025-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 암을 치료하기 위한 스플라이세오솜 표적화제로서의 플라디에놀리드 유도체
KR20210016375A (ko) 2018-06-01 2021-02-15 에자이 알앤드디 매니지먼트 가부시키가이샤 스플라이싱 조절제 항체-약물 접합체 및 사용 방법
AU2019279012A1 (en) * 2018-06-01 2020-12-24 Eisai R&D Management Co., Ltd. Methods of using splicing modulators
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
CN116096752B (zh) * 2020-06-05 2025-10-28 卫材R&D管理有限公司 抗bcma抗体-药物缀合物及其使用方法
JP2023553588A (ja) 2020-11-04 2023-12-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 骨髄異形成症候群（ｍｄｓ）のバイオマーカー及びその使用方法
EP4361136A4 (en) * 2021-06-18 2025-08-13 Univ Cordoba Compound for the treatment of glioblastoma
CN113876771B (zh) * 2021-11-12 2022-09-23 中国医学科学院基础医学研究所 一种靶向pabpc1的小分子药物及其在慢性髓系白血病中的应用
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
EP4570796A1 (en) 2022-11-07 2025-06-18 Eisai R&D Management Co., Ltd. Method for producing macrolide compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI311558B (en) * 2001-02-01 2009-07-01 Mercian Corporatio Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
AU2003252299A1 (en) 2002-07-31 2004-02-16 Eisai Co., Ltd. Novel physiologically active substance
CA2494536C (en) 2002-07-31 2011-10-04 Mercian Corporation A 12-membered ring macrolide active substance
WO2004037212A2 (en) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
AU2003284469B2 (en) 2002-11-29 2008-02-21 Eisai R&D Management Co., Ltd. Process for producing macrolide compound
AU2004292634B2 (en) 2003-11-27 2008-11-27 Eisai R&D Management Co., Ltd. DNA participating in hydroxylation of macrolide compound
ES2382987T3 (es) 2003-11-28 2012-06-15 Kanagawa Academy Of Science And Technology Método de detección de cáncer de hígado, diagnóstico de cáncer de hígado y curación del cáncer
JPWO2006003706A1 (ja) 2004-07-02 2008-04-17 株式会社プラスワンテクノ 組み合わせ計量技術
CA2574092C (en) 2004-07-20 2011-08-23 Eisai R & D Management Co., Ltd. Dna coding for polypeptide participating in biosynthesis of pladienolide
TW200716744A (en) * 2005-05-26 2007-05-01 Eisai R&D Man Co Ltd Genetically modified microorganism and process for production of macrolide compound using the microorganism
JPWO2007043621A1 (ja) 2005-10-13 2009-04-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 プラジエノライドｂ及びプラジエノライドｄの全合成方法
JPWO2008111464A1 (ja) * 2007-03-05 2010-06-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング異常を指標とする抗ガン剤の作用検定方法
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives

Also Published As

Publication number Publication date
MA39915A (fr) 2017-03-22
ME03417B (me) 2020-01-20
TWI634115B (zh) 2018-09-01
RU2016148887A (ru) 2018-06-18
CY1121550T1 (el) 2020-05-29
RU2707730C2 (ru) 2019-11-29
PL3143016T3 (pl) 2019-04-30
KR101710318B1 (ko) 2017-02-24
WO2015175594A1 (en) 2015-11-19
PH12016502249A1 (en) 2017-02-06
CN107074827A (zh) 2017-08-18
EP3143016A1 (en) 2017-03-22
US9481669B2 (en) 2016-11-01
BR112016026638B1 (pt) 2022-08-02
PH12016502249B1 (en) 2023-12-13
KR20170021899A (ko) 2017-02-28
NZ725603A (en) 2023-11-24
DK3143016T3 (en) 2019-04-08
RS58400B1 (sr) 2019-04-30
HUE041838T2 (hu) 2019-05-28
IL248529B (en) 2019-11-28
CA2947754C (en) 2024-01-02
CA2947754A1 (en) 2015-11-19
MX388580B (es) 2025-03-20
JP6067943B1 (ja) 2017-01-25
PE20170384A1 (es) 2017-05-11
ES2712401T3 (es) 2019-05-13
ZA201607354B (en) 2018-05-30
CN107074827B (zh) 2020-12-18
KR102146726B1 (ko) 2020-08-21
MA39915B1 (fr) 2019-05-31
JP2017505282A (ja) 2017-02-16
AU2015259237A1 (en) 2016-11-10
CL2016002835A1 (es) 2017-04-17
KR20160082256A (ko) 2016-07-08
SMT201900158T1 (it) 2019-05-10
EP3514154A1 (en) 2019-07-24
HRP20190432T1 (hr) 2019-04-19
AU2015259237B2 (en) 2019-08-15
SG11201609693XA (en) 2016-12-29
LT3143016T (lt) 2019-06-10
RU2019124012A (ru) 2019-08-12
SI3143016T1 (sl) 2019-04-30
UA119458C2 (uk) 2019-06-25
MY195081A (en) 2023-01-09
MX373324B (es) 2020-05-04
NZ764190A (en) 2023-11-24
MX2020004476A (es) 2021-12-08
EP3143016B1 (en) 2018-12-12
PT3143016T (pt) 2019-02-27
TW201625596A (zh) 2016-07-16
JO3668B1 (ar) 2020-08-27
RU2016148887A3 (es) 2018-12-11
EP3514154B1 (en) 2022-08-03
US20150329528A1 (en) 2015-11-19
TR201902328T4 (tr) 2019-03-21
IL248529A0 (en) 2016-12-29
BR112016026638A2 (es) 2017-08-15
AR100431A1 (es) 2016-10-05

Similar Documents

Publication Publication Date Title
MX2020004476A (es) Compuestos piridinicos de pladienolida y metodos de uso.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
TW201613901A (en) New compounds
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
JO3556B1 (ar) علاجات مدمجة لمعالجة السرطان
PH12016501791B1 (en) Muscarinic receptor agonists
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
EA201591925A1 (ru) Терапевтические композиции и их применение
MX392475B (es) Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso
IL254842B (en) Therapeutic preparations and methods for use in cancer treatment
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
PH12017500853B1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
IL261278A (en) Pharmaceutical compositions for the treatment of cancer
MX2020000135A (es) Nuevos compuestos de quinolinona.
PH12016501838A1 (en) Compounds and their methods of use
IL255169A0 (en) Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer
IL255168A0 (en) Treatment combination of an anti-pogatactic factor and an anti-cancer factor and compounds for the treatment of cancer
MY182809A (en) Compositions for the treatment of kidney and/or liver disease
GB2546703A (en) Compounds
HK1237265A1 (en) Combination therapy compositions and methods for treating cancers

Legal Events

Date Code Title Description
FG Grant or registration